Pharmacetical Newswire

Pharmaceutical News!

Press release distribution service
Pharmaceutical Links

Pharmanewswire.Com: Pharmaceutical News

Opioid-Induced Bowel Dysfunction (OBD or OIBD) Market, Therapeutics Landscape and Pipeline Review H2 2016

(PharmaNewsWire.Com, January 31, 2017 ) Opioid-Induced Bowel Dysfunction (OBD or OIBD) Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Opioid-Induced Bowel Dysfunction (OBD or OIBD) therapeutics industry report provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects.
Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-oesophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist.
Browse a Report Copy at: http://www.absolutereports.com/opioid-induced-bowel-dysfunction-obd-or-oibd-pipeline-review-h2-2016-10512156
The Opioid-Induced Bowel Dysfunction (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Opioid-Induced Bowel Dysfunction (OBD or OIBD) – Pipeline Review, H2 2016:
• ChironWells GmbH
• Orphomed Inc
• RaQualia Pharma Inc
• Vitality Biopharma Inc

Purchase a Report Copy at: http://www.absolutereports.com/purchase/10512156
Scope Opioid-Induced Bowel Dysfunction (OBD or OIBD) Pipeline Review Report-

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opioid-Induced Bowel Dysfunction (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (Toxicology)

Key Topics Covered:
1.Introduction
2.Opioid-Induced Bowel Dysfunction (OBD or OIBD) Overview
3.Opioid-Induced Bowel Dysfunction (OBD or OIBD) Therapeutics Development
4.Pipeline Products for Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview
5.Pipeline Products for Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Comparative Analysis
6.Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics under Development by Companies
7.Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics under Investigation by Universities/Institutes
8.Opioid-Induced Bowel Dysfunction (OBD or OIBD) Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Products under Development by Companies
13.Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Products under Investigation by Universities/Institutes
14.Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development
15.Opioid-Induced Bowel Dysfunction (OBD or OIBD) Drug Profiles
16.Opioid-Induced Bowel Dysfunction (OBD or OIBD) Dormant Projects
17.Opioid-Induced Bowel Dysfunction (OBD or OIBD) Discontinued Products
18.Opioid-Induced Bowel Dysfunction (OBD or OIBD) Featured News & Press Releases
And Continue…
Sample PDF of Opioid-Induced Bowel Dysfunction (OBD or OIBD) Pipeline Review H2 2016 Research Study at: http://www.absolutereports.com/enquiry/request-sample/10512156

This research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (OBD or OIBD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Ask Discount on Opioid-Induced Bowel Dysfunction (OBD or OIBD) Therapeutics Companies Review H2 2016 Research Report at: http://www.absolutereports.com/enquiry/request-discount/10512156
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.
Contact–
Mr. Ameya Pingaley
Absolute Reports
+1-408 520 9750
Email – sales@absolutereports.com

www.absolutereports.com



Absolute Reports

Ameya Pingaley

+1 408 520 9750

sales@absolutereports.com

Source: EmailWire.Com

Source: EmailWire.com


Pharmaceutical Sponsors

Free Biotech & Pharmaceutical Magazines

Pharmacy Newswire Video Feed

Pharmaceutical & Biotech Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:

IronPort Provides Email Management and Analysis for a Premier Health Care Solutions Provider
Pharmaceutical & Medical Packaging News
Medical Laboratory Observer

No credit cards, coupons, or promo codes required. Try it today!

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com, or contact us.
Copyright 2009 GroupWeb Media LLC
GroupWeb Media Network

Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
| i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
Pharmanewswire.com - Pharmaceutical Newswire and Press Release service of GroupWeb Media LLC